Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.
Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.
By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.
It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.
You may decide to join a clinical trial because:
- The treatment you receive will be at least the best available for your illness.
- Your health may improve because of the treatment you receive.
- You may receive a treatment you would not otherwise have access to.
- Your health will be carefully checked by the treatment team running the trial.
- You will be part of the worldwide effort to improve cancer treatment.
For more information on clinical trials please click here.
If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:
Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240
Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830
The Queen Elizabeth: Sue Yeend, +61 8 8222 6148
Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833
Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342
Current clinical trials for melanoma & other skin cancer
|Recruiting||A Phase Iii, Double-Blinded, Randomized, Placebo-Controlled Study Of Atezolizumab Plus Cobimetinib And Vemurafenib Versus Placebo Plus Cobimetinib And Vemurafenib In Previously Untreated Brafv600 Mutation−Positive Patients With Unresectable Locally Advanced Or Metastatic Melanoma. Protocol: Triplet C039262||Royal Adelaide Hospital|
|Recruiting||A Phase 3, randomized study of adjuvant immunotherapy with nivolumab combined with ipilimumab versus ipilimumab or nivolumab monotherapy after complete resection of stage IIIb/c/d or stage IV melanoma.||Royal Adelaide Hospital|
|Recruiting||CARPETS - A phase 1 parallel group study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with GD2-positive metastatic melanoma and refractory solid tumors.||Royal Adelaide Hospital|
|Recruiting||Checkmate 401 (Melanoma) Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma||Flinders Medical Centre|
|Not yet recruiting||DV3- MEL-01 A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.||Ashford Cancer Centre|
|Not Yet Recruiting||FLIGHT An Open Label Phase 1 Study Investigating the Effects of CDX-301 on the Safety, Clinical Activity, and Immune Priming of Glembatumumab Vedotin Combined with Pembrolizumab or Nivolumab in Unresectable or Metastatic Melanoma Patients Not Responding to the AntiPD1 Therapy||Royal Adelaide Hospital|
|Not yet recruiting||A Phase II Randomized, open-label, Multi-centre study of the safety and efficacy of IMCgp100 compared with Investigator choice in HLA-A*0201 positive patients with previously untreated advanced uveal melanoma.||Royal Adelaide Hospital|
|Recruiting||KEYNOTE 29 A Phase 1/2, Clinical Trial to Study the Safety & Tolerability of MK3475 + Pegylated Interferon alfa-2b (PEG-IFN) & MK-3475 + Ipilimumab (IPI) in subjects with advanced Melanoma||Royal Adelaide Hospital|
|Recruiting||MASTERKEY-265 - A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma||The Queen Elizabeth Hospital|
|Recruiting||TACTI mel TACTI-mel (Two ACTive Immunotherapeutics in melanoma): A multicentre, open label, dose escalation, Phase 1 study in patients with unresectable or metastatic melanoma receiving IMP321 (LAG- 3Ig fusion protein) as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab||Flinders Medical Centre|
|Recruiting||TROG 08/09 - A randomized trial of post operative radiation therapy following wide excision of neurotropic melanoma of the head and neck||Royal Adelaide Hospital|